AlphaTON Capital: Capture the Best of Telegram Economics at Steep Discount – Downloadable Initiation
Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com Rayk@capmarketsmedia.com
Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com Rayk@capmarketsmedia.com
IPO Edge hosted a fireside chat on Dec. 9 from the floor of the New York Stock Exchange during the Bloomberg Activism Forum 2025 with Steve Parish, Managing Partner, Equity Capital Markets at ICR Capital. The in-person interview was joined by...
Download the Complete Report Here By Brandon Hornback SOL Strategies Inc. (NASDAQ: STKE) is the premiere play on Solana’s (SOL) accelerated growth, packaged as an easily-accessible public equity. After a broad-based selloff in shares of digital asset treasury (DAT) companies,STKE...
Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com Rayk@capmarketsmedia.com
By Exec Edge Editorial Staff Vinson & Elkins advised Coterra Energy Inc. on a behind-the-meter power purchase agreement with PROPWR, a subsidiary of ProPetro Holding Corp., to develop a distributed microgrid at Coterra’s production sites in the New Mexico portion...
Download the Complete Report Here By Brandon Hornback REX American Resources Corp. (NYSE: REX) continued its long-running winning of streak, making it 21 straight profitable quarters. Ethanol volumes edged higher and operational discipline helped offset softer pricing, reinforcing REX’s position...
Read Exec Edge’s Initiation on REX Here Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com Rayk@capmarketsmedia.com
By Karen Roman Sequana Medical NV (BRU: SEQUA.BR) said it successfully implanted the alfapump device for treatment of recurrent or refractory ascites due to liver cirrhosis in two patients at the University of Pennsylvania. The alfapump is the first FDA-approved...
By Daniella Parra March Bio is developing MB-105, a first-in-class autologous CD5-targeted CAR-T cell therapy for relapsed/refractory T-cell lymphoma and other CD5-positive hematologic malignancies, they said. The company said the therapy employs a proprietary CAR design that enables selective targeting of...
Exec Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Chris Searles, co-founder and Chief Executive Officer, and Trevor Smith, co-founder and Chief Technology Officer of DxCheck. The in-person interview was joined by Editor-in-Chief John Jannarone and...